E.J. Whitten Foundation Prostate Cancer Research Centre Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04430192
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

E.J. Whitten Foundation Prostate Cancer Research Centre

Active Ingredients

Drugs in Phase 2 Trials (1)

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1